Stockreport

Adaptive and Genentech Partner to Use clonoSEQ® Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic Lymphocytic Leukemia Patients

Adaptive Biotechnologies Corporation  (ADPT) 
Last adaptive biotechnologies corporation earnings: 2/26 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: adhc.com
PDF SEATTLE, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the gene [Read more]